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Androgen receptors are widely distributed in several tissues, including vascular endothe-
lial and smooth muscle cells. Through classic cytosolic androgen receptors or mem-
brane receptors, testosterone induces genomic and non-genomic effects, respectively.
Testosterone interferes with the vascular function by increasing the production of pro-
inflammatory cytokines and arterial thickness. Experimental evidence indicates that sex
steroid hormones, such as testosterone modulate the synthesis and bioavailability of NO
and, consequently, endothelial function, which is key for a healthy vasculature. Of inter-
est, aging itself is accompanied by endothelial and vascular smooth muscle dysfunction.
Aging-associated decline of testosterone levels is accompanied by age-related diseases,
such as metabolic and cardiovascular diseases, indicating that very low levels of androgens
may contribute to cardiovascular dysfunction observed in these age-related disorders or,
in other words, that testosterone may have beneficial effects in the cardiovascular system.
However, testosterone seems to play a negative role in the severity of renal disease. In this
mini-review, we briefly comment on the interplay between aging and testosterone levels,
the vascular actions of testosterone and its implications for vascular aging. Renal effects
of testosterone and the use of testosterone to prevent vascular dysfunction in elderly are
also addressed.
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INTRODUCTION
Sex hormones, including testosterone, have important extrago-
nadal effects and experimental and clinical data point to important
effects of sex hormones on the cardiovascular system (Reckel-
hoff, 2005). There is intense debate on the role of testosterone
on cardiovascular function and cardiovascular disease (CVD).
Whereas high doses of testosterone have been associated with
sudden cardiac death and liver disease (Bagatell and Bremner,
1996), low levels are associated with the progression of ather-
osclerosis, production of pro-inflammatory cytokines, increased
arterial thickness, increased levels of glucose, total cholesterol, and
low-density lipoprotein, all important in CVD (Hak et al., 2002;
Miller et al., 2004; Francomano et al., 2010).
Although reduced testosterone levels in aging men are inti-
mately associated with several aspects of vascular injury, the
male sex1,2 is extensively mentioned as a risk factor for CVD,
with males having an earlier and higher prevalence of many
1According to the Department of Reproductive Health and Research,World Health
Organization (WHO), http://www.who.int/gender/whatisgender/en/), “Sex” refers
to the biological andphysiological characteristics that definemen andwomen;“Gen-
der” refers to the socially constructed roles, behaviors, activities, and attributes that
a given society considers appropriate for men and women.”
2As recently reviewed by Miller et al. (2011): “Sex,” a biological construct, refers
to biological differences defined by sex chromosomes (XX, XY) and the presence
of functional reproductive organs and sex steroids. “Gender,” a cultural construct,
refers to behaviors thought to be directed by specific stimuli or by psychosocial
expectations that result or accrue on the basis of assigned or perceived sex. Whereas
sex is considered a dichotomous variable; gender is a continuous variable as defined
by a range of characteristics that might vary with age, species (animals), or eth-
nicity (humans), geographical location, education, and culture. Most studies using
cardiovascular and metabolic-related diseases (Yang and Reckel-
hoff, 2011).
In this mini-review, we will briefly comment on the inter-
play between aging and testosterone levels, the vascular actions of
testosterone and its implications for vascular aging. Renal effects
of testosterone and the use of testosterone to prevent vascular
dysfunction in elderly are also addressed.
BRIEF BIOCHEMISTRY OF TESTOSTERONE SYNTHESIS AND
SIGNALING
More than 95% of testosterone, the principal male steroid hor-
mone from the androgens group, is produced by the testes and
secreted by the Leydig cells, after a series of enzymatic reac-
tions in the cholesterol molecule. Small amounts of testosterone
are also secreted by the zona reticularis of the adrenal glands
(Sa et al., 2009). In men, normal levels of testosterone range
from 10 to 30 nM, while much lower levels are found in women
(0.6–2.5 nM; Burger, 2002). Testosterone plays a major role in
the development of male reproductive tissues and is found in
mammals, reptiles, birds, and other vertebrates. In men, testos-
terone also promotes secondary sexual characteristics, such as
increased muscle, bone mass, and the growth of body hair
(Mooradian et al., 1987). Although adult human males pro-
duce about 10 times more testosterone than the female coun-
terparts, females are very sensitive to the hormone. In women
testosterone is synthesized by the theca cells of the ovaries, by
animals categorized by anatomical features and chromosomes can be described as
studies of “sex” differences.
www.frontiersin.org April 2012 | Volume 3 | Article 89 | 1
Lopes et al. Testosterone in aging
the placenta, as well as by the adrenal cortex (Bassil et al.,
2009).
In men, whereas around 7% of testosterone is reduced to
5α-dihydrotestosterone (DHT) by the cytochrome P450 enzyme
5α-reductase (an enzyme highly expressed in male accessory sex
organs and hair follicles), small amounts (around 0.5%) are
converted into estradiol by aromatase (CYP19A1, an enzyme
expressed in the brain, liver, adipose, and cardiovascular tissues).
DHT is more biologically active than testosterone since it binds to
the androgen receptor with a 15-fold higher affinity than testos-
terone (Thigpen et al., 1993; Randall, 1994; Meinhardt and Mullis,
2002; Askew et al., 2007).
Androgen receptors are widely distributed in several
cells/tissues, including vascular smooth muscle cells and endothe-
lial cells (Negro-Vilar, 1999). Through classic cytosolic androgen
receptors or membrane receptors, testosterone induces genomic
and non-genomic effects, respectively. The classical effects of
testosterone depends on its binding to the androgen receptor,
which acts as a transcription factor that upon association to the
androgen response element, modulates transcription, and pro-
tein synthesis. The non-genomic effects are rapidly produced, do
not require the association of androgen receptors to DNA and
therefore are insensitive to the inhibition of RNA and protein
synthesis, and involve the activation of various signaling path-
ways, including calcium-, protein kinase A-, protein kinase C-,
and mitogen-activated protein kinase (MAPK)-activated path-
ways (Bhasin and Jasuja, 2009). It is important to mention that
activation of androgen receptors may vary considering whether
naturally produced or commercially available hormones are being
used, as well as whether metabolic products of androgens are
being generated (e.g., testosterone, but not DHT, can be arom-
atized to 17β-estradiol) or whether androgen effects were tested
on tissues/cells derived from male or female animals (Elbaradie
et al., 2011; Toufexis and Wilson, 2012).
EVIDENCE FOR A ROLE OF TESTOSTERONE IN REGULATION
OF LONGEVITY
While the decrease in estrogen and progesterone occurs abruptly
in women, testosterone levels decline in men starts in the early
years of adulthood, with a 1–2% reduction per year, and persists
throughout life (Harman et al., 2001; Araujo and Wittert, 2011).
This reduction is often associated with CVD,metabolic syndrome,
insulin resistance, and atherosclerosis. The increased longevity has
also been accompanied by an increase in the number of men
with hypogonadism (Bassil et al., 2009). Commonly, testosterone
replacement improves cardiovascular and metabolic functions
(Ruige et al., 2011; Hyde et al., 2012). In addition, a prospective
observational study with men aged 70–96 years demonstrated that
low testosterone inmen, independent of pre-existing health condi-
tions, and other risk factors, is associated with increased mortality
risk (Fukai et al., 2011).
Decreased expression of cardiac β1-adrenergic receptors is
involved in many models of decompensate hypertrophy and
heart failure (Bisognano et al., 2000). A study conducted in
male Sprague-Dawley rats showed that low levels of testosterone
reduced β1-adrenoceptor mRNA, while testosterone replacement
produced a fourfold increase in β1-adrenoceptor mRNA levels.
Testosterone replacement also increased mRNA levels of andro-
gen receptor, Na+/Ca2+ exchanger, and L-type calcium channel
as well as heart weight (Golden et al., 2002). Therefore it is pos-
sible that aging-associated testosterone deficiency may contribute
to cardiovascular dysfunction in the elderly.
Although many studies indicate that low levels of testosterone
represent a risk factor for CVD, men have a higher prevalence
of CVD than women and this ratio narrows after menopause
(Lerner and Kannel, 1986). In general, explanations for the sex
differences in CVD point to a deleterious effect of testosterone
or the absence of the cardioprotective effects of estrogen in men
(Wu and von Eckardstein, 2003). As elegantly reviewed by Wu and
von Eckardstein (2003), a global evaluation of the relationship
between androgens and coronary heart disease (CAD) revealed
that the data are contradictory, and that is not yet possible to say
whether there is a direct association between levels of testosterone
or other androgens and CAD. In addition, although testosterone
levels in men are positively related to HDL and negatively to LDL,
in women this ratio is negative, suggesting that males and females
respond differently to androgens, and that some of the beneficial
effects of testosterone in men, may be deleterious in women.
Aging-associated CVDs are accompanied by structural and
functional changes in the heart and blood vessels. Cardiovascular
aging is manifested by maladaptation to stress, cardiac and vascu-
lar dysfunction, and heart failure.Aging-associatedmorphological
and functional changes of cardiac and vascular myocytes lead to
cardiac and vascular hypertrophy, fibrosis, decreased regenerative
capacity of cardiac stem cells/endothelial progenitor cells (EPCs),
increased myocyte death due to necrosis and apoptosis (Ungvari
et al., 2010; Shih et al., 2011). In the vasculature, increased arterial
wall thickening and generalized vascular stiffness are attributed
to vascular calcification, increased collagen content/elastin break-
down, and elevated levels of advanced glycation end products
(AGEs). In addition, endothelial dysfunction, vascular inflam-
mation, oxidative stress, vascular cell apoptosis also contribute
to aging-associated vascular dysfunction, which accelerates CAD,
heart failure, stroke, and dementia (Ungvari et al., 2010).
Aging is not only a prominent independent risk factor for
CVD, but it is also associated with decreased cognitive func-
tion. Of importance, there is strong evidence for a protective role
of testosterone in brain regions, including regions susceptible to
Alzheimer’s disease, such as the hippocampus (Pike et al., 2009).
Neuronal damage and apoptosis caused by oxidative stress, a hall-
mark in aging-associated cardiovascular dysfunction, can also be
inhibited by testosterone. Testosterone induces the activation of
extracellular-signal-regulated kinases (ERKs), which phosphory-
late the pro-apoptotic protein Bad, a member of the pro-apoptotic
Bcl-2 family, making it inactive, and increasing neuronal activ-
ity. It is known that regions like the hippocampus and cortical
regions have a large amount of androgen receptors (Simerly et al.,
1990). Interestingly, whereas testosterone inhibits oxidative stress
and apoptosis in the brain, our group has shown that testosterone
increases reactive oxygen species (ROS) generation (Chignalia
et al., 2012) and activates apoptotic pathways (unpublished data)
in vascular smooth muscle cells.
Sexual health has also becomemore importantwith the increas-
ing longevity in men and women. Erectile dysfunction markedly
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increases with age and men with increased sexual activity have
a higher level of bioavailable testosterone than men with erectile
dysfunction. Although erectile dysfunction is not a life threatening
condition, it directly affects the well-being, self-steam, interper-
sonal relationship and overall quality of life. It has been suggested
that approximately 15–25% of men over the age of 50 years are
expected to have serum testosterone levels that fall below that of
the threshold considered normal in men between 20 and 40 years
of age (Jockenhovel, 2004). Testosterone improves a great num-
ber of androgen deficiency symptoms in the aging male (Giuliano
et al., 2004; Amar et al., 2005). Several studies have shown that
normal testosterone levels are important for sexual function, and
the correlation between hypogonadism and sexual dysfunction
is well documented (Shabsigh et al., 2006; Blute et al., 2009;
Buvat et al., 2010). For example, testosterone is important for
normal erectile function because it regulates nitric oxide (NO),
phosphodiesterase-5 (PDE5) levels, and it maintains penile mus-
cle cells (Blute et al., 2009). However, it is important to point
out that the main effects of testosterone are not to maintain an
erection per se. Conversely, testosterone is much more impor-
tant for the global aspects of sexual function including libido,
orgasm, ejaculatory volume, preserving the general function of
the cavernosumand the vasculature involved in the erectile process
(Lazarou and Morgentaler, 2005). Accordingly, clinical trials have
demonstrated that replacement of testosterone levels in hypogo-
nadal men improves overall sexual function and restores vascular
damage in the cavernosal tissue (Seftel et al., 2004; Bassil et al.,
2009; Romanelli et al., 2010). In addition, testosterone is essen-
tial for health and well-being (Bassil et al., 2009) as well as the
prevention of osteoporosis (Tuck and Francis, 2009).
TESTOSTERONE SIGNALING IN VASCULAR AGING
Experimental data demonstrate that testosterone induces relax-
ation of many vascular beds, including coronary, mesenteric, iliac,
renal, and femoral arteries in several animal species such as rab-
bit, dog, rat, pig, both in vivo and in vitro conditions. In general,
most studies indicate that the relaxation induced by testosterone
involves endothelium-independent mechanisms, potassium
channel-opening actions and calcium antagonistic effects (Yue
et al., 1995; Chou et al., 1996; Crews and Khalil, 1999; Murphy and
Khalil, 1999; English et al., 2000, 2002; Deenadayalu et al., 2001).
However, testosterone, as well as other sex steroid hormones
(e.g., estrogen) also modulate NO release and, consequently, influ-
ence endothelial function (Miller and Mulvagh, 2007). Physi-
ological concentrations of testosterone (and DHT) have been
shown to increase endothelial synthesis of NO via activation
of the extracellular-signal-regulated kinase (ERK) 1/2 and phos-
phatidylinositol 3-OH kinase (PI3K)/Akt cascades (Goglia et al.,
2010). Similarly, in rat aortic strips, testosterone significantly
increased NO production, via androgen receptor and calcium
influx (Campelo et al., 2012). Using endothelial cell cultures these
authors demonstrated that testosterone enhances NO production
by directly acting in the endothelial cells via PKC- and MAPK-
dependent pathways. Testosterone also significantly increased
DNA synthesis indicating that androgens may also modulate vas-
cular endothelial cell growth (Campelo et al., 2012). In addition,
testosterone, at physiological concentrations and via androgen
receptor activation, induces proliferation, migration, and colony
formation activity of EPCs (Foresta et al., 2008), indicating that the
release of EPCs by bone marrow may be an additional mechanism
by which testosterone modulates endothelial function (Foresta
et al., 2006).
A criticism to the studies reporting the relaxation effects of
testosterone in blood vessels is that generally the effects are
observed at supraphysiological doses/concentrations, and when
physiological concentrations of testosterone were used, the studies
were inconclusive, with some showing positive effects, and others
neutral or even deleterious effects of testosterone (Wu and von
Eckardstein, 2003). Furthermore, since most of the studies on the
effects of androgens on NO production have been conducted in
co-culture systems, it is necessary to assess the direct impact of
testosterone on endothelial cell growth and function.
Sader et al. (2001) observed that although low doses of testos-
terone per se induce vasodilation (brachial artery flow-mediated
dilatation, FMD) in healthy men, estradiol supplementation is
associated with enhanced arterial vasodilation. The mechanisms
by which testosterone and estrogen induce NO release are inter-
twined, since through the P450 aromatase, testosterone can be
converted to estrogen. An excellent review by Miller and Mul-
vagh (2007) has addressed the mechanisms by which testosterone
and estrogen modulate endothelial cells function and NO release.
As summarized in Figure 1, the mechanism of action of testos-
terone in endothelial cell includes classic steroid receptor activa-
tion via modulation of gene transcription (genomic), and also
membrane receptor activation coupled to fast intracellular sig-
naling (non-genomic). Activation of both estrogen and androgen
receptors modulates endothelial function by mechanisms involv-
ing activation of Akt, MAPK, tyrosine kinase, and Giα, culmi-
nating in NO synthase activation and release of NO. The aging-
associated decrease in testosterone levels may thus compromise
this important pathway in vascular tone control.
English and colleagues, in a study with arteries from young and
elderly male Wistar rats demonstrated that despite normal con-
tractile responses to prostaglandin F2α, vessels of elderly animals
were less sensitive to the vasodilatory effects of testosterone com-
pared to vessels from young animal. This was accompanied by
hypertrophy of vascular myocytes, and greater thickening of the
smooth muscle layer, in aged animals (English et al., 2000).
Yildiz et al. (2005) demonstrated that the relaxation induced by
testosterone in human internal mammary artery is dependent on
large conductanceCa2+-activatedK+ channels (BKCa). This chan-
nel is key in the regulation of vascular tone and arterial diameter
and is target to various vasoconstrictor and vasodilator agents.
As shown in Figure 1, aging decreases the expression of BKCa
channels in coronary smooth muscle and increases endothelial
responses to vasoconstrictor agents, which can contribute to the
reduced vasodilator response to testosterone in elderly and also
increase the risk of vasospasm,myocardial ischemia,and infarction
in these individuals (Marijic et al., 2001).
Ripple et al. (1999) showed that, in androgen-sensitive human
prostate cancer (LNCaP), androgens increasemitochondrial dehy-
drogenase activity, levels of cellular peroxides andhydroxyl radicals
and the area fraction of mitochondria per cell. The oxidative stress
in LNCaPwas abolished in the presence of rotenone and antimycin
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FIGURE 1 | Mechanisms involved in the regulation of vascular function
by testosterone. Smooth muscle cell: The relaxation induced by testosterone
is dependent on large conductance Ca2+-activated K+ channels (BKCa). Aging
decreases the expression of BKCa, which can determine the reduced
vasodilator response to testosterone in elderly. Testosterone induces NADPH
oxidase-dependent ROS generation. NO can react with •O−2 forming
peroxynitrite (ONOO−). This decreases NO availability and consequently
reduces vasodilator responses. Testosterone also stimulates COX-1/COX-2
and ET-1 pathways. Endothelial cell: Through the P450 aromatase,
testosterone can be converted to estrogen. Activation of estrogen and
androgen receptors modulates endothelial function by mechanisms involving
release of NO via NO synthase. Abbreviations: AR, androgen receptor; ER
estrogen receptor; Akt, serine/threonine kinase; BKCa, large conductance
Ca2+-activated K+ channels; ERKs, extracellular-signal-regulated kinases;
eNOS, endothelial NO synthase; Giα, guanine nucleotide regulator protein
subunit that inhibits guanylate cyclase; MAPK, mitogen-activated protein
kinase; •O−•2 , superoxide anion; ONOO−, peroxynitrite; PGs, prostaglandins;
TxA2, thromboxane A2. Aging-associated decline in testosterone levels, as
well as mechanisms that contribute to aging-associated endothelial
dysfunction are depicted in red.
A (electron transport system inhibitors), and abrogated in the
presence of alpha-tocopherol succinate. These data indicate that
ROS generation induced by androgen in LNCaP involves mito-
chondrial pathways and is sensitive to antioxidants. On the other
hand, Hwang et al. (2011) demonstrated that treatment of Leydig
cells with low doses of testosterone has cytoprotective effects by
decreasing ROS and lipid peroxides. However, cytotoxic effects,
due to increased ROS generation, were found with high doses of
testosterone. Although data from our laboratory demonstrate that
testosterone induces ROS generation in VSMCs (Chignalia et al.,
2012), which can culminate in decreased NO bioavailability and
reduce vasodilator responses, it is not known whether this effect is
altered in senescent VSMCs.
Testosterone also stimulates thromboxane synthase as well as
COX-1 and COX-2, which are key enzymes in the synthesis of
prostaglandins (Cheuk et al., 2000; Song et al., 2004). Accordingly,
the aging-associated decrease in testosterone levels may inter-
fere with vascular function via changes in the thromboxane/COX
pathway (Figure 1).
de Souza Rossignoli et al. (2010), in a study to determine
the effects of declining levels of testosterone, as occurs in aging,
and testosterone replacement on vascular function, found that
orchidectomy enhanced the maximum responses of the portal
vein to phenylephrine. However, testosterone replacement had no
effect on these responses. Yet in this study, orchidectomy-induced
increased maximum response to phenylephrine was not altered by
a NOS inhibitor alone or combined with indomethacin. Interest-
ingly, the increased response was abolished in the presence of ETA
and ETB receptor antagonists (BQ-123 and BQ-788, respectively),
suggesting that increased contractile responses to phenylephrine
induced by decreases in plasma testosterone, involves activation of
ETAandETB receptors. The relationship between testosterone and
endothelin-1 (ET-1) is complex.Whereas substantial data support
the idea that testosterone positively modulates ET-1 levels and ET-
1-mediated vasoconstrictor responses, other reports indicate that
ET-1 levels are higher in conditions associated with low levels of
testosterone, as in hypogonadism (Tostes et al., 2008).
The regulation of resting membrane potential is mostly depen-
dent on the voltage-dependent potassiumchannels (Kv), and func-
tional changes of these channels may impair vascular function.
Kv plays a key role in endothelial cells function and is decreased
in stroke-prone spontaneously hypertensive rats (Sadanaga et al.,
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2002). Zhou et al. (2008) investigated the effects of testosterone
deprivation (castration – 6months) as well as the effects of testos-
terone replacement therapy on the function of Kv channels in
rat thoracic aortic VSMCs. In this study long-term deprivation of
endogenous testosterone decreased the expression of Kv1.5 protein,
which culminated in reduced function of Kv channels.Testosterone
replacement restored the impaired function of Kv, which suggests
that testosterone deficiency in aging may impair vascular func-
tion via a decrease of endothelial and vascular smooth muscle Kv
channels.
As already mentioned, aging is accompanied by endothelial
dysfunction (Yildiz, 2007). There is extensive discussion on the
mechanisms by which the aging process attenuates endothelium-
dependent dilatation. Enhanced production of endothelium-
derived vasoconstrictor prostanoids, decreased NO bioavailability,
increased expression/activity of ET-1, and augmented ROS gen-
eration are all potential mechanisms involved in aging-associated
endothelial injury and vascular dysfunction (Mombouli and Van-
houtte, 1999; Blackwell et al., 2004; Vanhoutte et al., 2009). The
generation of superoxide anion (•O−2 ) results in rapid forma-
tion of hydrogen peroxide (H2O2) via mitochondrial manganese
superoxide dismutase (MnSOD). NO can react with •O−2 forming
peroxynitrite (ONOO−) that inactivates MnSOD and may also
uncouple NO synthase. Both reactions decrease the availability of
NO and consequently reduce vasodilator responses (Yildiz, 2007).
Decreased NO bioavailability is also associated with endothe-
lial NO synthase (eNOS) dysfunction since uncoupled eNOS
is a source of •O−2 in the vasculature. Accordingly, removal of
endothelial cells, as well as pharmacological inhibition of NOS,
reverses the vascular increased •O−2 production of aged vessels.
In aging, eNOS uncoupling seems to be associated with a reduc-
tion of the cofactor tetrahydrobiopterin availability (Delp et al.,
2008; Yang et al., 2009) rather than to a deficiency of l-arginine
substrate concentration (Gates et al., 2007). In addition, eNOS
knockout male mice have a significantly shorter lifespan than their
wild type controls and exhibit accelerated aging-dependent cardiac
dysfunction. Regarding ET-1 and aging, plasma ET-1 concentra-
tions increase with age (Battistelli et al., 1996; Donato et al., 2009;
Goel et al., 2010),ET-1-mediated vasoconstriction is augmented in
older adults (Thijssen et al., 2007;VanGuilder et al., 2007) and syn-
thesis of ET-1 is greater in cultured aortic endothelial cells obtained
from older donors compared with young ones (Tokunaga et al.,
1992). Finally, inhibition of ET-1 signaling with an ETA receptor
antagonist improves endothelial dysfunction in arteries from old
mice, while not affecting dilation in young controls (Donato et al.,
2009). As discussed above, testosterone has been shown to modu-
late each of these mechanisms that contribute to aging-associated
endothelial dysfunction. However, whether decreased testosterone
levels are directly associated with the endothelial dysfunction and
increased incidence of CVDs remains controversial.
Hypogonadism is a condition associated with endothelial dys-
function (Akishita et al., 2007; Foresta et al., 2008). A study where
male patients were submitted to examination of vasomotor func-
tion of the brachial artery and intima-media thickness (IMT)
of the carotid artery, showed that low levels of testosterone are
associated with endothelial dysfunction, independent of age, body
mass index, hypertension, hyperlipidemia, diabetes mellitus, or
current smoking, suggesting a protective effect of testosterone on
endothelial function (Akishita et al., 2007).
THE USE OF TESTOSTERONE TO PREVENT VASCULAR
DYSFUNCTION IN ELDERLY
Testosterone replacement therapy has been shown to decrease total
cholesterol, low-density lipoprotein, and triglycerides, to increase
high density lipoprotein, and also to inhibit fatty streak forma-
tion, indicating that androgens may have protective effects against
atherosclerosis (Nettleship et al., 2007, 2009; Saad et al., 2008).
Likewise, testosterone has been shown to improve hemody-
namic parameters in patients and animal models of heart failure,
especially via a reduction in peripheral vascular resistance and
increased coronary blood flow through vasodilation and via direct
effects in the cardiac tissue (e.g., by inhibition of cardiac cAMP-
phosphodiesterases; Bordallo et al., 2011; Nguyen et al., 2011).
Through the measurement of pulse wave velocity, a technique
that allows to analyze arterial stiffness (decreased compliance),
vascular disease, and also to predict future cardiovascular events
(Boutouyrie et al., 2002; Pizzi et al., 2006), Yaron and colleagues
reported that pulse wave velocity was significantly higher in men
with hypogonadism. Transdermal testosterone replacement ther-
apy increased androgen bioavailability and decreased pulse wave
velocity, indicating that testosterone replacement can diminish
arterial stiffness associated with male hypogonadism (Yaron et al.,
2009).
The decline in testosterone levels observed with aging occurs
at a time when prostate diseases start to emerge. Excellent results
have been found with new testosterone preparations via different
routes of administration (Titus et al., 2005). 5α-reductase inhi-
bition (with finasteride), which is used in the treatment of men
with benign prostatic hyperplasia (McConnell et al., 1992), also
improves the quality of life of these patients.
Decreased levels of dehydroepiandrosterone (DHEA), a pre-
cursor of testosterone, are also associated with aging-related dis-
eases. Although its mechanisms of action remain poorly under-
stood,DHEA replacement therapy exerts positive anti-aging, anti-
obesity, anti-atherosclerosis, anti-diabetic, and anti-osteoporosis
effects (Gomez-Santos et al., 2011).
The above-mentioned data indicate that testosterone actions
on the vasculature are beneficial and that low levels of testosterone
are detrimental to cardiovascular function. Testosterone replace-
ment may be beneficial in the treatment of diseases characteristic
of elderly, but the positive cardiovascular benefits resulting from
it need to be clearly demonstrated in large clinical trials.
If, in one hand, androgens seem to confer cardioprotection, on
the other hand androgens can increase blood pressure and induce
renal dysfunction, which may adversely influence the cardiovas-
cular system. For example, chronic infusion of DHT increased
sodium and water reabsorption and subsequently blood pressure
in Sprague-Dawley rats (Quan et al., 2004). Further support to the
idea that testosterone may have deleterious effects on renal func-
tion derives from studies in animals with arterial hypertension.
Orchidectomy in male SHR prevents aging-associated increase in
renal vascular resistance and reduces renal superoxide production
(Reckelhoff et al., 2005). In addition, physiological concentra-
tions of DHT increase dihydroethidium fluorescence in cultured
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mesangial cells from SHR (Reckelhoff et al., 2005), whereas tem-
pol, a SOD mimetic, reduces ROS generation and blood pres-
sure in SHR (Fortepiani and Reckelhoff, 2005). Considering that
testosterone also induces ROS generation in VSMCs from SHR
(Chignalia et al., 2012) and that superoxide, the major ROS found
in kidneys, reduces NO bioavailability and increases renal vaso-
constriction (Reckelhoff and Romero, 2003; Yildiz, 2007), it is
possible that testosterone may directly contribute to renal dam-
age and vascular dysfunction via ROS generation. Furthermore,
in the renal wrap model of hypertension, castration of male rats
decreases renal damage, and DHT treatment of castrated males,
reverses it, suggesting that androgens may directly contribute to
the development of renal failure (Ji et al., 2005).
However, studies also suggest a renoprotective role for testos-
terone. For example, reduced levels of testosterone correlates
with the development of albuminuria, a marker of diabetic renal
disease, and castration of streptozotocin-treated rats potentiates
diabetes-associated albuminuria (Xu et al., 2008). In addition, clin-
ical studies show reduced levels of testosterone in diabetic patients
(Laaksonen et al., 2004; Ding et al., 2006; Kapoor et al., 2007),
raising the possibility that the severity of renal disease in these
patients is partially due to a decrease in testosterone levels. A study
conducted in 36 outpatient centers in Belgium, France, Germany,
Italy, the Netherlands, Spain, Sweden, and the UK between Feb-
ruary 2006 and March 2007 evaluated the effects of testosterone
replacement therapy on insulin resistance in hypogonadal men
with type 2 diabetes. Testosterone replacement reduced insulin
resistance and improved glycemic control in the overall popula-
tion (Jones et al., 2011). Furthermore,promising results arose from
a study in which testosterone replacement was used for 2 years in
type 2 diabetic male patients, who had the first ischemic stroke.
Several parameters were improved by testosterone replacement
on those patients, such as body mass index, glycated hemo-
globin, cholesterol, triglycerides, and low-density lipoproteins.
Furthermore, only 7.1% of the patients receiving testosterone
replacement had a secondary stroke compared with 16.6% in the
control group (Morgunov et al., 2011). These data indicate that
testosterone replacement may be important to reduce cardiovas-
cular risk factors, especially in type 2 diabetes associated with the
hypogonadism condition.
It is unknown whether renal dysfunction or renal protection
by testosterone is associated with direct effects of testosterone on
the renal cells, or indirect effects of the hormone (e.g., in the renal
vasculature). Since human renal proximal tubule and cortical col-
lecting duct cells express enzymes involved in androgen synthesis
(Quinkler et al., 2003) as well as androgen receptors (Kimura et al.,
1993), onemay speculate that testosterone regulates renal function
by direct mechanisms.
Although data on testosterone and androgens being
bad/deleterious or good/beneficial to the cardiovascular and renal
systems are still very controversial, in general, experimental evi-
dence indicates that testosterone is essential for the equilibrium
in the actions of many endothelium-derived vasoactive agents as
well as for the appropriate function of structural components of
these systems (Table 1). The aging-associated decrease in testos-
terone levels may disrupt these signals and therefore contribute to
cardiovascular and renal dysfunction observed in elderly.
CONCLUSION AND PERSPECTIVES
Even though evidence indicates that vascular damage characteris-
tic of aging may be improved or even reversed with testosterone
replacement therapy,more studies are needed to confirm the puta-
tive beneficial cardiovascular effects of testosterone therapy. In
addition, the long-termeffects of testosterone replacement therapy
need to be carefully addressed. For example, whereas short-term
testosterone treatment has been shown to produce a wide range
of benefits (it improves hemodynamic parameters, cognitive and
sexual function, mood, muscle mass and strength), the beneficial
effects may not be maintained (the gain of muscle mass, strength,
and quality of life are not maintained at 6months post-treatment
Table 1 | Cardiovascular and renal effects mediated by androgens.
Androgen Cell/tissue Effect Reference
Testosterone Heart ↑ β1-Adrenoceptor, ↑ androgen receptor, ↑
Na+/Ca2+ exchanger, ↑ L-type calcium channel
Golden et al. (2002)
Testosterone Cultured VSMCs ↑ ROS Chignalia et al. (2012)
Testosterone/
dihydrotestosterone
Human endothelial cells, blood vessels ↑ ERK ½, ↑ PI3K, ↑ eNOS, ↑ NO Goglia et al. (2010), Miller
and Mulvagh (2007)
Testosterone Brachial artery ↑ FMD Sader et al. (2001)
Testosterone Human internal mammary artery ↑ BKCa activation Yildiz et al. (2005)
Testosterone Rat epididymis, thoracic aortae, and
mesenteric arteries
↑ COX-1 and COX-2 Cheuk et al. (2000), Song
et al. (2004)
Testosterone Rat thoracic aorta ↑ Kv channels Zhou et al. (2008)
Testosterone Endothelial cells ↑ EPCs Foresta et al. (2008)
Dihydrotestosterone Kidney ↑ Sodium and water reabsorption Quan et al. (2004)
Dihydrotestosterone Mesangial cells ↑ ROS Reckelhoff et al. (2005)
FMD, brachial artery flow-mediated dilatation; COX, cyclooxygenase; eNOS, endothelial nitric oxide synthases; EPC, endothelial progenitor cells; ERK 1/2, extracellular-
signal-regulated kinase (ERK) 1/2; PI3K, phosphatidylinositol 3-OH kinase; ROS, reactive oxygen species; NO, nitric oxide; VSMC, vascular smooth muscle
cell.
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with testosterone in frail elderlymen;O’Connell et al., 2011). Does
the same happen with the cardiovascular effects (are the benefits
sustained or not)? What is the optimal duration of anabolic hor-
monal intervention? Are any possible side effects (e.g., prostatic
disease and erythrocytosis) overruled by the beneficial cardiovas-
cular effects? Do physical exercise, diet, and other lifestyle options,
in conjunction with pharmacological testosterone replacement,
improve beneficial cardiovascular effects of hormone therapy?
These questions clearly illustrate that the cardiovascular benefits
of testosterone therapy for age-related declines are not yet as clear
as they may seem.
ACKNOWLEDGMENTS
FAPESP (Fundaçao deAmparo a Pesquisa do Estado de Sao Paulo)
and CNPq (Conselho Nacional de Desenvolvimento Cientifico e
Tecnologico), Brazil.
REFERENCES
Akishita, M., Hashimoto, M., Ohike, Y.,
Ogawa, S., Iijima, K., Eto, M., and
Ouchi, Y. (2007). Low testosterone
level is an independent determinant
of endothelial dysfunction in men.
Hypertens. Res. 30, 1029–1034.
Amar,E.,Grivel,T.,Hamidi,K.,Lemaire,
A., and Giuliano, F. (2005). Age-
ing men’s sexual functions decline
and the erectile dysfunction (ED)
increase. Prog. Urol. 15, 6–9.
Araujo, A. B., and Wittert, G. A. (2011).
Endocrinology of the aging male.
Best Pract. Res. Clin. Endocrinol.
Metab. 25, 303–319.
Askew, E. B., Gampe, R. T. Jr., Stan-
ley, T. B., Faggart, J. L., and Wil-
son, E. M. (2007). Modulation of
androgen receptor activation func-
tion 2 by testosterone and dihy-
drotestosterone. J. Biol. Chem. 282,
25801–25816.
Bagatell,C. J., andBremner,W. J. (1996).
Androgens inmen–uses and abuses.
N. Engl. J. Med. 334, 707–714.
Bassil, N., Alkaade, S., and Morley, J.
E. (2009). The benefits and risks of
testosterone replacement therapy: a
review. Ther. Clin. Risk. Manag. 5,
427–448.
Battistelli, S., Gori, S., Borgogni, T., and
Manasse, G. (1996). Variation in the
plasma endothelin levels in relation
to age. Minerva Cardioangiol. 44,
111–114.
Bhasin, S., and Jasuja, R. (2009). Selec-
tive androgen receptor modulators
as function promoting therapies.
Curr. Opin. Clin. Nutr. Metab. Care
12, 232–240.
Bisognano, J. D., Weinberger, H. D.,
Bohlmeyer,T. J., Pende,A.,Raynolds,
M. V., Sastravaha, A., Roden, R.,
Asano, K., Blaxall, B. C., Wu, S. C.,
Communal, C., Singh, K., Colucci,
W., Bristow, M. R., and Port, D.
J. (2000). Myocardial-directed over-
expression of the human beta(1)-
adrenergic receptor in transgenic
mice. J. Mol. Cell. Cardiol. 32,
817–830.
Blackwell, K. A., Sorenson, J. P.,
Richardson, D. M., Smith, L. A.,
Suda, O., Nath, K., and Katu-
sic, Z. S. (2004). Mechanisms
of aging-induced impairment of
endothelium-dependent relaxation:
role of tetrahydrobiopterin. Am. J.
Physiol. Heart Circ. Physiol. 287,
H2448–H2453.
Blute, M., Hakimian, P., Kashanian,
J., Shteynshluyger, A., Lee, M., and
Shabsigh, R. (2009). Erectile dys-
function and testosterone deficiency.
Front. Horm. Res. 37, 108–122.
Bordallo, J., Cantabrana, B., Suarez,
L., and Sanchez, M. (2011).
Testosterone inhibits cAMP-
phosphodiesterases in heart extracts
from rats and increases cAMP levels
in isolated left atria. Pharmacology
87, 155–160.
Boutouyrie, P., Tropeano, A. I., Asmar,
R., Gautier, I., Benetos, A., Lacol-
ley, P., and Laurent, S. (2002). Aortic
stiffness is an independent predic-
tor of primary coronary events in
hypertensive patients: a longitudinal
study. Hypertension 39, 10–15.
Burger, H. G. (2002). Androgen pro-
duction in women. Fertil. Steril.
77(Suppl. 4), S3–S5.
Buvat, J., Maggi, M., Gooren, L., Guay,
A. T., Kaufman, J., Morgentaler, A.,
Schulman, C., Tan, H. M., Torres,
L. O., Yassin, A., and Zitzmann, M.
(2010). Endocrine aspects of male
sexual dysfunctions. J. Sex.Med. 7(Pt
2), 1627–1656.
Campelo, A. E., Cutini, P. H., and
Massheimer, V. L. (2012). Testos-
terone modulates platelet aggrega-
tion and endothelial cell growth
through nitric oxide pathway. J.
Endocrinol. 213, 77–87.
Cheuk, B. L., Leung, P. S., Lo, A. C., and
Wong, P. Y. (2000). Androgen con-
trol of cyclooxygenase expression in
the rat epididymis. Biol. Reprod. 63,
775–780.
Chignalia, A. Z., Schuldt, E., Camargo,
L.,Montezano,A. C. I.,Callera,G. E.,
Laurindo, F. R., Lopes, L. R., Avellar,
M. C.W., Carvalho,M. H. C., Fortes,
Z. B., Touyz, R. M., and Tostes,
R. C. (2012). Testosterone induces
vascular smooth muscle cell migra-
tion by NADPH oxidase and c-SRC-
dependent pathways. Hypertension
(in press).
Chou, T. M., Sudhir, K., Hutchison, S. J.,
Ko,E.,Amidon,T.M.,Collins,P., and
Chatterjee, K. (1996). Testosterone
induces dilation of canine coronary
conductance and resistance arteries
in vivo. Circulation 94, 2614–2619.
Crews, J. K., and Khalil, R. A. (1999).
Antagonistic effects of 17 beta-
estradiol, progesterone, and testos-
terone on Ca2+ entry mechanisms
of coronary vasoconstriction. Arte-
rioscler. Thromb. Vasc. Biol. 19,
1034–1040.
de Souza Rossignoli, P., Pereira, O.
C., and Chies, A. B. (2010).
Orchidectomy enhances the effects
of phenylephrine in rat isolated por-
tal vein. Clin. Exp. Pharmacol. Phys-
iol. 37, 368–374.
Deenadayalu, V. P., White, R. E., Stal-
lone, J. N., Gao, X., and Gar-
cia, A. J. (2001). Testosterone
relaxes coronary arteries by open-
ing the large-conductance, calcium-
activated potassium channel. Am.
J. Physiol. Heart Circ. Physiol. 281,
H1720–H1727.
Delp, M. D., Behnke, B. J., Spier,
S. A., Wu, G., and Muller-Delp,
J. M. (2008). Ageing diminishes
endothelium-dependent vasodilata-
tion and tetrahydrobiopterin con-
tent in rat skeletal muscle arterioles.
J. Physiol. (Lond.) 586, 1161–1168.
Ding, E. L., Song, Y., Malik, V. S.,
and Liu, S. (2006). Sex differences
of endogenous sex hormones and
risk of type 2 diabetes: a system-
atic review and meta-analysis. JAMA
295, 1288–1299.
Donato, A. J., Gano, L. B., Eskurza, I.,
Silver, A. E., Gates, P. E., Jablonski,
K., and Seals, D. R. (2009). Vascular
endothelial dysfunction with aging:
endothelin-1 and endothelial nitric
oxide synthase. Am. J. Physiol. Heart
Circ. Physiol. 297, H425–H432.
Elbaradie, K., Wang, Y., Boyan, B. D.,
and Schwartz, Z. (2011). Rapid
membrane responses to dihy-
drotestosterone are sex dependent
in growth plate chondrocytes. J.
Steroid Biochem. Mol. Biol. doi:
10.1016/j.jsbmb.2011.12.009. [Epub
ahead of print].
English, K. M., Jones, R. D., Jones, T.
H., Morice, A. H., and Channer, K.
S. (2000). Aging reduces the respon-
siveness of coronary arteries from
male Wistar rats to the vasodilatory
action of testosterone. Clin. Sci. 99,
77–82.
English, K. M., Jones, R. D., Jones, T. H.,
Morice, A. H., and Channer, K. S.
(2002). Testosterone acts as a coro-
nary vasodilator by a calcium antag-
onistic action. J. Endocrinol. Invest.
25, 455–458.
Foresta, C., Caretta, N., Lana, A., De
Toni, L., Biagioli, A., Ferlin, A., and
Garolla, A. (2006). Reduced number
of circulating endothelial progenitor
cells in hypogonadal men. J. Clin.
Endocrinol. Metab. 91, 4599–4602.
Foresta, C., Zuccarello, D., De Toni,
L., Garolla, A., Caretta, N., and
Ferlin, A. (2008). Androgens stim-
ulate endothelial progenitor cells
through an androgen receptor-
mediated pathway. Clin. Endocrinol.
(Oxf.) 68, 284–289.
Fortepiani, L. A., and Reckelhoff, J. F.
(2005). Role of oxidative stress in
the sex differences in blood pressure
in spontaneously hypertensive rats.
J. Hypertens. 23, 801–805.
Francomano, D., Bruzziches, R., Natali,
M., Aversa, A., and Spera, G. (2010).
Cardiovascular effect of testosterone
replacement therapy in aging male.
Acta Biomed. 81(Suppl. 1), 101–106.
Fukai, S., Akishita, M., Yamada, S.,
Ogawa, S., Yamaguchi, K., Kozaki,
K., Toba, K., and Ouchi, Y. (2011).
Plasma sex hormone levels and mor-
tality in disabled older men and
women. Geriatr. Gerontol. Int. 11,
196–203.
Gates, P. E., Boucher, M. L., Sil-
ver, A. E., Monahan, K. D., and
Seals, D. R. (2007). Impaired flow-
mediated dilation with age is not
explained by L-arginine bioavail-
ability or endothelial asymmet-
ric dimethylarginine protein expres-
sion. J. Appl. Physiol. 102, 63–71.
Giuliano, F., Tostain, J., and Rossi, D.
(2004). Testosterone and male sexu-
ality: basic research and clinical data.
Prog. Urol. 14, 783–790.
Goel, A., Su, B., Flavahan, S., Lowen-
stein, C. J., Berkowitz, D. E., and
Flavahan, N. A. (2010). Increased
endothelial exocytosis and genera-
tion of endothelin-1 contributes to
constriction of aged arteries. Circ.
Res. 107, 242–251.
www.frontiersin.org April 2012 | Volume 3 | Article 89 | 7
Lopes et al. Testosterone in aging
Goglia, L., Tosi, V., Sanchez, A.
M., Flamini, M. I., Fu, X. D.,
Zullino, S., Genazzani, A. R., and
Simoncini, T. (2010). Endothelial
regulation of eNOS, PAI-1 and t-PA
by testosterone and dihydrotestos-
terone in vitro and in vivo. Mol.
Hum. Reprod. 16, 761–769.
Golden, K. L., Marsh, J. D., and Jiang,
Y. (2002). Castration reduces mRNA
levels for calcium regulatory pro-
teins in rat heart. Endocrine 19,
339–344.
Gomez-Santos, C., Larque, E.,
Granero, E., Hernandez-Morante,
J. J., and Garaulet, M. (2011).
Dehydroepiandrosterone-sulphate
replacement improves the human
plasma fatty acid profile in plasma
of obese women. Steroids 76,
1425–1432.
Hak, A. E., Witteman, J. C., de Jong,
F. H., Geerlings, M. I., Hofman, A.,
and Pols, H. A. (2002). Low levels
of endogenous androgens increase
the risk of atherosclerosis in elderly
men: the Rotterdam study. J. Clin.
Endocrinol. Metab. 87, 3632–3639.
Harman, S. M., Metter, E. J., Tobin, J.
D., Pearson, J., and Blackman, M. R.
(2001). Longitudinal effects of aging
on serum total and free testosterone
levels in healthy men. Baltimore
Longitudinal Study of Aging. J. Clin.
Endocrinol. Metab. 86, 724–731.
Hwang, T. I., Liao, T. L., Lin, J. F., Lin, Y.
C., Lee, S. Y., Lai,Y. C., and Kao, S. H.
(2011). Low-dose testosterone treat-
ment decreases oxidative damage in
TM3 Leydig cells.Asian J. Androl. 13,
432–437.
Hyde,Z.,Norman,P. E., Flicker, L.,Han-
key, G. J., Almeida, O. P., McCaul,
K. A., Chubb, S. A., and Yeap, B. B.
(2012). Low free testosterone pre-
dicts mortality from cardiovascu-
lar disease but not other causes:
the health in men study. J. Clin.
Endocrinol. Metab. 97, 179–189.
Ji, H., Menini, S., Mok, K., Zheng,
W., Pesce, C., Kim, J., Mulroney, S.,
and Sandberg, K. (2005). Gonadal
steroid regulation of renal injury
in renal wrap hypertension. Am. J.
Physiol. Renal Physiol. 288, F513–
F520.
Jockenhovel, F. (2004). Testosterone
therapy – what, when and to whom?
Aging Male 7, 319–324.
Jones, T. H., Arver, S., Behre, H. M.,
Buvat, J., Meuleman, E., Moncada,
I., Morales, A. M., Volterrani, M.,
Yellowlees, A., Howell, J. D., and
Channer, K. S. (2011). Testosterone
replacement in hypogonadal men
with type 2 diabetes and/or meta-
bolic syndrome (the TIMES2 study).
Diabetes Care 34, 828–837.
Kapoor, D., Aldred, H., Clark, S., Chan-
ner, K. S., and Jones, T. H. (2007).
Clinical and biochemical assess-
ment of hypogonadism in men with
type 2 diabetes: correlations with
bioavailable testosterone and vis-
ceral adiposity. Diabetes Care 30,
911–917.
Kimura, N., Mizokami, A., Oonuma,
T., Sasano, H., and Nagura, H.
(1993). Immunocytochemical local-
ization of androgen receptor with
polyclonal antibody in paraffin-
embedded human tissues. J. His-
tochem. Cytochem. 41, 671–678.
Laaksonen, D. E., Niskanen, L., Pun-
nonen, K., Nyyssonen, K., Tuo-
mainen, T. P., Valkonen, V. P., Salo-
nen, R., and Salonen, J. T. (2004).
Testosterone and sex hormone-
binding globulin predict the meta-
bolic syndrome and diabetes in
middle-aged men. Diabetes Care 27,
1036–1041.
Lazarou, S., and Morgentaler, A. (2005).
Hypogonadism in the man with
erectile dysfunction:what to look for
and when to treat. Curr. Urol. Rep. 6,
476–481.
Lerner, D. J., and Kannel, W. B. (1986).
Patterns of coronary heart disease
morbidity andmortality in the sexes:
a 26-year follow-up of the Framing-
ham population. Am. Heart J. 111,
383–390.
Marijic, J., Li, Q., Song, M., Nishimaru,
K., Stefani, E., and Toro, L. (2001).
Decreased expression of voltage-
andCa(2+)-activated K(+) channels
in coronary smooth muscle during
aging. Circ. Res. 88, 210–216.
McConnell, J. D., Wilson, J. D., George,
F.W.,Geller, J.,Pappas,F., andStoner,
E. (1992). Finasteride, an inhibitor
of 5 alpha-reductase, suppresses pro-
static dihydrotestosterone in men
with benign prostatic hyperpla-
sia. J. Clin. Endocrinol. Metab. 74,
505–508.
Meinhardt, U., and Mullis, P. E. (2002).
The essential role of the aro-
matase/p450arom. Semin. Reprod.
Med. 20, 277–284.
Miller,V. M., Kaplan, J. R., Schork, N. J.,
Ouyang, P., Berga, S. L., Wenger, N.
K., Shaw, L. J., Webb, R. C., Mallam-
palli, M., Steiner, M., Taylor, D. A.,
Bairey Merz, C. N., and Reckelhoff,
J. F. (2011). Strategies and methods
to study sex differences in cardiovas-
cular structure and function: a guide
for basic scientists. Biol. Sex Differ. 2,
14.
Miller,V. M., and Mulvagh, S. L. (2007).
Sex steroids and endothelial func-
tion: translating basic science to clin-
ical practice. Trends Pharmacol. Sci.
28, 263–270.
Miller, V. M., Tindall, D. J., and
Liu, P. Y. (2004). Of mice, men,
and hormones. Arterioscler. Thromb.
Vasc. Biol. 24, 995–997.
Mombouli, J. V., and Vanhoutte, P.
M. (1999). Endothelial dysfunction:
from physiology to therapy. J. Mol.
Cell. Cardiol. 31, 61–74.
Mooradian, A. D., Morley, J. E., and
Korenman, S. G. (1987). Biological
actions of androgens. Endocr. Rev. 8,
1–28.
Morgunov, L., Denisova, I. A.,
Rozhkova, T. I., Stakhovskaia,
L. V., and Skvortsova, V. I. (2011).
Androgenic deficit and its treatment
in stroke male patients with diabetes
mellitus type II. Zh. Nevrol. Psikhi-
atr. Im. S. S. Korsakova. 111(8 Pt 2),
21–24.
Murphy, J. G., and Khalil, R. A. (1999).
Decreased [Ca(2+)](i) during inhi-
bition of coronary smooth mus-
cle contraction by 17beta-estradiol,
progesterone, and testosterone. J.
Pharmacol. Exp. Ther. 291, 44–52.
Negro-Vilar, A. (1999). Selective andro-
gen receptor modulators (SARMs):
a novel approach to androgen
therapy for the new millennium.
J. Clin. Endocrinol. Metab. 84,
3459–3462.
Nettleship, J. E., Jones, R. D., Channer,
K. S., and Jones, T. H. (2009). Testos-
terone and coronary artery disease.
Front. Horm. Res. 37, 91–107.
Nettleship, J. E., Jones, T. H., Channer,
K. S., and Jones, R. D. (2007). Phys-
iological testosterone replacement
therapy attenuates fatty streak for-
mation and improves high-density
lipoprotein cholesterol in the Tfm
mouse: an effect that is indepen-
dent of the classic androgen receptor.
Circulation 116, 2427–2434.
Nguyen, C. T., Aaronson, A., Morris-
sey, R. P., Agarwal, M., Willix, R. D.,
and Schwarz, E. R. (2011). Myths
and truths of growth hormone and
testosterone therapy in heart fail-
ure. Expert Rev. Cardiovasc. Ther. 9,
711–720.
O’Connell, M. D., Roberts, S. A.,
Srinivas-Shankar, U., Tajar, A., Con-
nolly, M. J., Adams, J. E., Oldham,
J. A., and Wu, F. C. (2011). Do
the effects of testosterone on mus-
cle strength, physical function, body
composition, and quality of life per-
sist six months after treatment in
intermediate-frail and frail elderly
men? J. Clin. Endocrinol. Metab. 96,
454–458.
Pike, C. J., Carroll, J. C., Rosario, E.
R., and Barron, A. M. (2009). Pro-
tective actions of sex steroid hor-
mones in Alzheimer’s disease. Front.
Neuroendocrinol. 30, 239–258.
Pizzi, O., Brandão, A. A., Magalhães, M.
E. C., Pozzan, R., and Brandão, A. P.
(2006). Pulse wave velocity. Braz. J.
Hypertens. 13, 4.
Quan, A., Chakravarty, S., Chen, J. K.,
Chen, J. C., Loleh, S., Saini, N.,
Harris, R. C., Capdevila, J., and
Quigley, R. (2004). Androgens aug-
ment proximal tubule transport.
Am. J. Physiol. Renal Physiol. 287,
F452–F459.
Quinkler, M., Bumke-Vogt, C.,
Meyer, B., Bahr, V., Oelk-
ers, W., and Diederich, S.
(2003). The human kidney is a
progesterone-metabolizing and
androgen-producing organ. J. Clin.
Endocrinol. Metab. 88, 2803–2809.
Randall, V. A. (1994). Role of 5 alpha-
reductase in health and disease.Bail-
lieres Clin. Endocrinol. Metab. 8,
405–431.
Reckelhoff, J. F. (2005). Sex steroids,
cardiovascular disease, and hyper-
tension: unanswered questions and
some speculations. Hypertension 45,
170–174.
Reckelhoff, J. F., and Romero, J. C.
(2003). Role of oxidative stress in
angiotensin-induced hypertension.
Am. J. Physiol. Regul. Integr. Comp.
Physiol. 284, R893–R912.
Reckelhoff, J. F., Yanes, L. L., Iliescu, R.,
Fortepiani, L. A., and Granger, J. P.
(2005). Testosterone supplementa-
tion in aging men and women: pos-
sible impact on cardiovascular-renal
disease. Am. J. Physiol. Renal Physiol.
289, F941–F948.
Ripple, M. O., Hagopian, K., Oberley,
T. D., Schatten, H., and Weindruch,
R. (1999). Androgen-induced oxida-
tive stress in human LNCaP prostate
cancer cells is associated with mul-
tiple mitochondrial modifications.
Antioxid. Redox Signal. 1, 71–81.
Romanelli, F., Sansone, A., and Lenzi,
A. (2010). Erectile dysfunction in
aging male. Acta Biomed. 81(Suppl.
1), 89–94.
Ruige, J. B., Mahmoud, A. M., De Bac-
quer, D., and Kaufman, J. M. (2011).
Endogenous testosterone and car-
diovascular disease in healthy men:
a meta-analysis. Heart 97, 870–875.
Sa, E. Q., Sa, F. C., Guedes, A. D., and
Verreschi, I. T. (2009). Serum testos-
terone and cardiovascular disease in
men. Arq. Bras. Endocrinol. Metabol.
53, 915–922.
Saad, F., Gooren, L. J., Haider, A., and
Yassin, A. (2008). A dose-response
study of testosterone on sexual
dysfunction and features of the
metabolic syndrome using testos-
terone gel and parenteral testos-
terone undecanoate. J. Androl. 29,
102–105.
Frontiers in Physiology | Vascular Physiology April 2012 | Volume 3 | Article 89 | 8
Lopes et al. Testosterone in aging
Sadanaga, T., Ohya, Y., Ohtsubo, T.,
Goto,K., Fujii, K., andAbe, I. (2002).
Decreased 4-aminopyridine sensi-
tive K+ currents in endothelial cells
from hypertensive rats. Hypertens.
Res. 25, 589–596.
Sader, M. A., McCredie, R. J., Grif-
fiths, K. A., Wishart, S. M.,
Handelsman, D. J., and Celer-
majer, D. S. (2001). Oestradiol
improves arterial endothelial func-
tion in healthy men receiving testos-
terone. Clin. Endocrinol. (Oxf.) 54,
175–181.
Seftel, A. D., Mack, R. J., Secrest, A. R.,
and Smith, T. M. (2004). Restora-
tive increases in serum testosterone
levels are significantly correlated to
improvements in sexual function-
ing. J. Androl. 25, 963–972.
Shabsigh,R., Rajfer, J.,Aversa,A., Traish,
A. M., Yassin, A., Kalinchenko, S. Y.,
and Buvat, J. (2006). The evolving
role of testosterone in the treatment
of erectile dysfunction. Int. J. Clin.
Pract. 60, 1087–1092.
Shih, H., Lee, B., Lee, R. J., and Boyle, A.
J. (2011). The aging heart and post-
infarction left ventricular remodel-
ing. J. Am. Coll. Cardiol. 57, 9–17.
Simerly, R. B., Chang, C., Muramatsu,
M., and Swanson, L. W. (1990). Dis-
tribution of androgen and estrogen
receptor mRNA-containing cells in
the rat brain: an in situ hybridiza-
tion study. J. Comp. Neurol. 294,
76–95.
Song, D., Arikawa, E., Galipeau, D.,
Battell, M., and McNeill, J. H.
(2004). Androgens are necessary
for the development of fructose-
induced hypertension. Hypertension
43, 667–672.
Thigpen, A. E., Silver, R. I., Guileyardo,
J. M., Casey, M. L., McConnell, J. D.,
andRussell,D.W. (1993). Tissue dis-
tribution and ontogeny of steroid 5
alpha-reductase isozyme expression.
J. Clin. Invest. 92, 903–910.
Thijssen, D. H., Rongen, G. A., van
Dijk, A., Smits, P., and Hopman, M.
T. (2007). Enhanced endothelin-1-
mediated leg vascular tone in healthy
older subjects. J. Appl. Physiol. 103,
852–857.
Titus, M. A., Schell, M. J., Lih, F.
B., Tomer, K. B., and Mohler,
J. L. (2005). Testosterone and
dihydrotestosterone tissue levels in
recurrent prostate cancer. Clin. Can-
cer Res. 11, 4653–4657.
Tokunaga, O., Fan, J., Watanabe,
T., Kobayashi, M., Kumazaki, T.,
and Mitsui, Y. (1992). Endothe-
lin. Immunohistologic localization
in aorta and biosynthesis by cultured
human aortic endothelial cells. Lab.
Invest. 67, 210–217.
Tostes, R. C., Fortes, Z. B., Callera,
G. E., Montezano, A. C., Touyz,
R. M., Webb, R. C., and Car-
valho, M. H. (2008). Endothelin,
sex and hypertension. Clin. Sci. 114,
85–97.
Toufexis,D. J., andWilson,M. E. (2012).
Dihydrotestosterone differentially
modulates the cortisol response of
the hypothalamic-pituitary-adrenal
axis in male and female rhesus
macaques, and restores circadian
secretion of cortisol in females.
Brain Res. 1429, 43–51.
Tuck, S. P., and Francis, R. M. (2009).
Testosterone,bone andosteoporosis.
Front. Horm. Res. 37, 123–132.
Ungvari, Z., Kaley, G., de Cabo, R., Son-
ntag, W. E., and Csiszar, A. (2010).
Mechanisms of vascular aging: new
perspectives. J. Gerontol. A Biol. Sci.
Med. Sci. 65, 1028–1041.
Van Guilder, G. P., Westby, C. M.,
Greiner, J. J., Stauffer, B. L., and
DeSouza,C.A. (2007). Endothelin-1
vasoconstrictor tone increases with
age in healthy men but can be
reduced by regular aerobic exercise.
Hypertension 50, 403–409.
Vanhoutte, P. M., Shimokawa, H., Tang,
E. H., and Feletou, M. (2009).
Endothelial dysfunction and vascu-
lar disease. Acta Physiol. (Oxf.) 196,
193–222.
Wu, F. C., and von Eckardstein, A.
(2003). Androgens and coronary
artery disease. Endocr. Rev. 24,
183–217.
Xu, Q., Wells, C. C., Garman, J. H.,
Asico, L., Escano,C. S., and Maric, C.
(2008). Imbalance in sex hormone
levels exacerbates diabetic renal dis-
ease. Hypertension 51, 1218–1224.
Yang, X. P., and Reckelhoff, J. F.
(2011). Estrogen, hormonal replace-
ment therapy and cardiovascular
disease. Curr. Opin. Nephrol. Hyper-
tens. 20, 133–138.
Yang, Y. M., Huang, A., Kaley, G., and
Sun, D. (2009). eNOS uncoupling
and endothelial dysfunction in aged
vessels. Am. J. Physiol. Heart Circ.
Physiol. 297, H1829–H1836.
Yaron, M., Greenman, Y., Rosenfeld, J.
B., Izkhakov, E., Limor, R., Osher,
E., Shenkerman, G., Tordjman, K.,
and Stern, N. (2009). Effect of
testosterone replacement therapy on
arterial stiffness in older hypogo-
nadal men. Eur. J. Endocrinol. 160,
839–846.
Yildiz, O. (2007). Vascular smooth mus-
cle and endothelial functions in
aging. Ann. N. Y. Acad. Sci. 1100,
353–360.
Yildiz, O., Seyrek, M., Gul, H., Un, I.,
Yildirim, V., Ozal, E., Uzun, M., and
Bolu, E. (2005). Testosterone relaxes
human internal mammary artery
in vitro. J. Cardiovasc. Pharmacol. 45,
580–585.
Yue, P., Chatterjee, K., Beale, C., Poole-
Wilson, P. A., and Collins, P. (1995).
Testosterone relaxes rabbit coronary
arteries and aorta. Circulation 91,
1154–1160.
Zhou, P., Fu, L., Pan, Z., Ma, D.,
Zhang, Y., Qu, F., Guo, L., Cao,
J., Gao, Q., and Han, Y. (2008).
Testosterone deprivation by castra-
tion impairs expression of voltage-
dependent potassium channels in
rat aorta. Eur. J. Pharmacol. 593,
87–91.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 25 January 2012; accepted: 25
March 2012; published online: 10 April
2012.
Citation: Lopes RAM, Neves KB,
Carneiro FS and Tostes RC (2012)
Testosterone and vascular function
in aging. Front. Physio. 3:89. doi:
10.3389/fphys.2012.00089
This article was submitted to Frontiers
in Vascular Physiology, a specialty of
Frontiers in Physiology.
Copyright © 2012 Lopes,Neves, Carneiro
and Tostes. This is an open-access article
distributed under the terms of the Cre-
ative Commons Attribution Non Com-
mercial License, which permits non-
commercial use, distribution, and repro-
duction in other forums, provided the
original authors and source are credited.
www.frontiersin.org April 2012 | Volume 3 | Article 89 | 9
